MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder

Background The bifunctional methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase (MTHFD2) has been reported to play an oncogenic role in various types of cancers. However, the function of MTHFD2 in urothelial carcinomas of bladder (UCB) and its association with tumor immune infiltration remains unknown. We aim to examine the suitability of MTHFD2 to be a novel biomarker of bladder cancer and whether MTHFD2 is linked to immune infiltration. Methods RNA sequencing data and clinical information (bladder cancer samples: normal samples = 414: 19) were downloaded from The Cancer Genome Atlas official website. Western blot analysis was performed to detect MTHFD2 expression in human bladder cancer (BLCA) cells and normal urothelial cell line SV-HUC-1. Associations between MTHFD2 expression and clinicopathological features were analyzed using Mann Whitney U test or Kruskal-Wallis H test. The “survival” and “survminer” packages were utilized to plot Kaplan-Meier survival curves. Moreover, the gene set enrichment analysis (GSEA) was conducted using a clusterProfiler package. The correlation of MTHFD2 expression with immune infiltration level was estimated using the single sample GSEA (ssGSEA) algorithm. Furthermore, associations between MTHFD2 and immune checkpoint genes were evaluated using the correlation analysis. Results Transcriptome analysis manifested that MTHFD2 was highly expressed in UCB tissues than normal bladder tissues, which was further confirmed by western blot analysis in human BLCA cells and SV-HUC-1 cells. Moreover, MTHFD2 high expression was significantly associated with the advanced disease progression. Also, the high expression of MTHFD2 was correlated with poor prognosis, and MTHFD2 was considered as an independent prognostic factor for disease specific survival. Furthermore, a number of cancer-related pathways were enriched in MTHFD2 high group, including NF-κB activation, JAK/STAT, and cancer immunotherapy by PD1 blockade. Several immune checkpoint molecules were also strongly associated with MTHFD2 expression, including PDCD1, CD274, CTLA4, CD276, LAG3, HAVCR2, and TIGIT. Conclusions MTHFD2 expression was remarkably elevated in UCB, suggesting that MTHFD2 could be a promising biomarker for BLCA as well as novel target for anti-cancer immunotherapy since its close association with immune infiltration. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-022-09606-0.


Background
Bladder cancer (BLCA) is the fourth most prevalent cancer expected to be diagnosed in men in the United States, with estimated 61,700 new cases and 12,120 deaths in 2022 [1]. The incidence rate in males is 3 to 5 times higher than that in females [2]. It is obvious that patients suffer a lot from this kind of disease which needs lifelong surveillance (with cystoscopy, bladder biopsy, and urine cytology) and invasive treatment. At the same time, remarkable morbidity and mortality of BLCA contribute to tremendous economic burdens on families and health care systems, causing serious social problems [3]. The major histology type of BLCA is urothelial carcinomas, where non-muscle-invasive BLCA (NMIBC) accounts for approximately 75% and the remaining is muscle-invasive BLCA (MIBC) [4]. The treatment regimens and efficacy of BLCA may be influenced by multiple factors, such as the disease stage, grade, associated risk factors, and other clinical characteristics. The current standard treatment for NMIBC is transurethral resection (TUR), followed by intravesical mitomycin C or bacillus Calmette-Guerin (BCG) if necessary [5]. For MIBC, the front-line treatment is neoadjuvant chemotherapy combined with radical cystectomy [6]. Besides, MIBC is more aggressive and serious because 5-year survival rate of MIBC patients with localized disease is 60% and that of patients with metastases is less than 10% [7].
Urothelial carcinomas of the bladder (UCB) are histologically classified as high-grade bladder urothelial carcinoma (HGBC) and low-grade bladder urothelial carcinoma (LGBC). HGBC is more likely to have a high risk of recurrence, progression, and metastasis than LGBC. To our knowledge, both histological grade and tumornode-metastasis (TNM) stage are closely related to prognosis [5,8]. However, there is no significant molecular marker able to predict prognosis or direct the treatment of UCB. Therefore, effective and reliable molecular markers are in high demand.
Previous literatures have proposed several potential prognostic factors for UCB, including urinary biomarkers, tissue biomarkers, blood biomarkers. Serial measurements of UroVysion FISH in urine were reported to have strong relationship with both cancer recurrence and progression. AUA/SUO expert opinion pointed that a clinician may use UroVysion FISH to assess response to intravesical BCG [9,10]. For bladder tissue biomarkers, nuclear accumulation of p53 was found prognostic in MIBC, as well as inactivating mutation of Rb combined with other cell cycle regulatory proteins [11,12]. Survivin and Bcl-2 family were also reported to be associated with bladder cancer recurrence and mortality among patients who performed radical cystectomy [13]. Meanwhile, FGFR3, GATA3, FOXA1, ERBB2, ERCC2, CDKN2A, STAG2,CDH1,CDH3,estrogen receptor-β etc., were reported to characterize patients with MIBC into distinct molecular subtypes, which could potentially predict prognosis [14,15]. Insulin growth factor binding proteins (IGFBPs), transforming growth factor-β1(TGF-β1) and VEGF, as UCB blood biomarkers, were illustrated to be associated with adverse survival outcomes [16]. However, these biomarkers have not yet been applied to clinical use as they are still unable to guide clinical decision-making in UCB. Thus, we intend to uncover more potential molecular candidates for UCB. The bifunctional methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase (MTHFD2) is a mitochondrial enzyme that assumes a pivotal role in one-carbon folate metabolic. It was recently reported as a potential target for anticancer therapy. MTHFD2 has been observed to exert oncogenic effects in a variety of cancers. The non-metabolic functions of MTHFD2 in cancers have aroused considerable research interests. The high level of MTHFD2 has been shown to be connected with the poor prognosis of solid and hematological malignancies. For colorectal cancer cell lines, MTHFD2 could facilitate cell proliferation, migration, and cycle entry, and suppress cell apoptosis [17]. In breast cancer, MTHFD2 was reported to activate the AKT signaling pathway to promote tumorigenesis [18]. Meanwhile, MTHFD2 could accelerate tumorigenesis and metastasis via the AKT/glycogen synthase kinase-3β (GSK-3β)/βcatenin signaling pathway in lung adenocarcinoma [19] and via the STAT3 signaling pathway in ovarian cancer [20]. Recently, MTHFD2 was found to affect bladder cancer cell growth by activating CDK2 [21]. All these observations indicated that MTHFD2 is tightly associated with the tumorigenesis of various cancer types.
However, the functional importance of MTHFD2 is still poorly investigated in BLCA. Intuitively, we suspect that MTHFD2 might play a role in BLCA progression as Conclusions: MTHFD2 expression was remarkably elevated in UCB, suggesting that MTHFD2 could be a promising biomarker for BLCA as well as novel target for anti-cancer immunotherapy since its close association with immune infiltration. Keywords: Urothelial carcinomas of bladder, MTHFD2, The Cancer Genome Atlas website, Biomarker, Immune infiltrates, Prognosis well as its prognosis. In this study, we provided lines of evidences to elucidate the correlation between MTHFD2 and prognosis of patients with UCB. For immune infiltrates, MTHFD2 expression was positively correlated with T helper 2 (Th2) cells, Th1 cells, macrophages, activated dendritic cells (aDCs), and T gamma delta (Tgd) immune cells. We conclude that MTHFD2 could be a promising biomarker for BLCA as well as a novel target for anti-cancer immunotherapy due to its close association with immune infiltration.

Data acquisition
RNA sequencing (RNA-seq) data and clinical information were downloaded from BLCA project level 3 HTSeq-Fragments Per Kilobase per Million (FPKM) in The Cancer Genome Atlas (TCGA, https:// portal. gdc. cancer. gov/). FPKM data were converted to transcripts per million (TPM) data, and corresponding values were transformed using log2. Four hundred fourteen patients (tumor samples: normal samples = 414:19) with both RNA-seq data and clinical information were enrolled in this study. RNA-seq datasets from various bladder cancer cell lines such as UMUC10 and BFTC905, were downloaded from the Cancer Cell Line Encyclopedia (CCLE).
T24 and TCCSUP cell lines were cultured in complete Dulbecco's Modified Eagle Media (Gibco), and SV-HUC-1 cell line was incubated in complete Ham's F12K (Kaighn's) modified medium (Gibco). All cells were cultured in a humidified CO 2 condition at 37 °C.

Protein extraction and western blot analysis
Proteins were extracted with Radio-Immunoprecipitation assay buffer (Shanghai Biotechwell, Shanghai, China), and protease and phosphatase inhibitors were added immediately before use. The protein concentration in the supernatant was measured using a bicinchoninic acid assay kit (Shanghai Biotechwell). Western blot analysis was performed following standard procedures. The primary antibodies employed in this study were MTHFD2 antibody (1:1000, mouse, Abcam) and β-actin antibody (1:2000, mouse, Shanghai Biotechwell). Secondary antibodies were horseradish peroxidase-coupled goat anti-mouse antibodies (12,000, Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA).

Tumor immune estimation
The tumor immune estimation resource, version 2 (TIMER2.0) website (http:// timer. cistr ome. org/) can robustly estimate the connection of immune infiltrates with other factors, such as gene expression, mutation status, somatic copy-number variants, and clinical outcome. Meanwhile, users could explore cancer-related associations based on TCGA [22]. We predicted the expression difference of MTHFD2 between tumor and normal tissue in different tumors from "Gene_DE" module of TIMER2.0.
Gene Set Variation Analysis (GSVA) was an unsupervised gene set enrichment method that can be applied for detecting subtle pathway activity changes within highly heterogeneous data sets [23]. The correlation of MTHFD2 expression with immune infiltration level (24 types of immune cells) was estimated using the single sample gene set enrichment analysis (ssGSEA) algorithm by an R GSVA package. The analysis was conducted with the use of the different markers of various immune cells from the literature published in Cell [24]. The R ggplot2 package was adopted to assess the association between MTHFD2 expression and immune checkpoint molecule expression, including programmed cell death 1 (PDCD1), CD274, cytotoxic T lymphocyte-associated antigen 4 (CTLA4), CD276, colony-stimulating factor 1 receptor (CSF1R), indoleamine 2,3 dioxygenase-1 (IDO1), lymphocyte activation gene 3 (LAG3), hepatitis A virus cellular receptor 2 (HAVCR2), and T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT). One day before transfection, plate cells in 24-well plate with 500 μl of growth medium without antibiotics. At the time of transfection, cells will be 50-70% confluent. For each well to be transfected, RNAi duplex-Lipofectamine RNAiMAX complexes were prepared as follows: a. Dilute 6 pmol RNAi duplex in 50 μl Opti-MEM Medium without serum. Mix gently. b. Mix Lipofectamine RNAiMAX gently before use, then dilute 1 μl in 50 μl Opti-MEM Medium. Mix gently. c. Combine the diluted RNAi duplex with the diluted Lipofectamine ™ RNAiMAX. Mix gently and incubate for 10-20 min at room temperature. Add the RNAi duplex-Lipofectamine RNAiMAX complexes to each well containing cells. This gives a final volume of 600 μl and a final RNA concentration of 10 nM. Mix gently by rocking the plate back and forth. Change medium after harvesting 4-6 h and incubate the cells 24-48 h at 37 °C in a CO2 incubator until we carry out further experiments.

Cell proliferation and cell circle analysis
Cell proliferation was measured using the Cell Counting Kit-8(CCK8), which was purchased from Dojindo Molecular Technologies. We performed the experiment following manufacturer-recommended procedures. Cells were seeded at a density of 1 × 10^4/mL in 96-well plates. We record the absorbance at 450 nm at 0 h,24 h,48 h,72 h, 96 h using a microplate reader. Cell circle analysis was assessed by flow cytometry according to standard protocols. Briefly, cells were washed twice in PBS, stained with propidium iodide (PI) solution for 30 min at 37 °C, analyzed by flow cytometry using FlowJo 10.

Immunohistochemical staining
Tumor and normal tissues of three BLCA patients were obtained from Peking University People's Hospital with ethics committee approval. We performed immunohistochemical staining steps followed as each instruction of products. The tissues were dewaxed in xylene, rehydrated in graded ethanol and incubated with EDTA (pH = 9.0, Maxim Biotech) buffer for antigen retrieval. Endogenous peroxidase was blocked by 6% hydrogen peroxide for 10 min. After washing with PBS three times, sections were incubated with primary antibody (MTHFD2, 1:100, mouse, Abcam) overnight at 4 °C. Then sections were further incubated with a secondary antibody EnVision ™ +/ HRP labelled anti-rabbit antibody (Dako) for half an hour. DAB method was used for color development.

Statistical analysis
R(v.3.6.3) was applied for all data processing and statistical analysis. RNA-seq analysis of differential expression in UCB tissues (n = 414) and normal bladder tissues (n = 19) was performed with DEseq2. Genes with an absolute log2 fold change (log2FC) > 0.7 and adjusted p-value (p. adjust) < 0.01 were considered as differentially expressed genes. Then we ranked 56,493 genes from UCB samples in TCGA by their relative MTHFD2 expression in the top 50th percentile and the bottom 50th percentile for GSEA using a clusterProfiler package. We perform GSEA analysis of essential pathways in UMUC10 and BFTC905 cell lines in the same way. The C2.cp.v7.2.symbols.gmt was utilized for GSEA with the random combinatorial count set as 1000. Gene set collections were acquired from MsigDB. Moreover, false discovery rate (FDR) < 0.25 with p.adjust < 0.05 was considered significant.
The association between MTHFD2 expression and clinicopathological features was analyzed by the Mann Whitney U test or the Kruskal-Wallis H test using a ggplot2 package. The probabilistic receiver-operating characteristic (pROC) Package was applied to plot ROC curve. For Kaplan-Meier survival curves, the survival and survminer packages were utilized to conduct the survival analysis based on MTHFD2 expression along with some clinical features. We determined the cut-off value of MTHFD2 expression by its median. p < 0.05 was considered to be significant (ns, p ≥ 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001).

Clinical characteristics of patients with UCB
The clinical information of 414 patients with UCB in TCGA is presented in Table 1. There were 234 (56.5%) patients less than or equal to 70 years old at the time of diagnosis and 180 (43.5%) patients over 70 years old, with 109 (26.3%) females and 305 (73.7%) males. As for race information, 330 (83.1%) patients were white, 44 (11.1%) were Asian, and 23 (5.8%) were black or African American. In terms of body mass index, 153 (42.0%) patients were less than or equal to 25, and 211 (58.0%) patients were over 25

MTHFD2 was upregulated in various cancer types including UCB
As reflected by TIMER analysis, MTHFD2 expression was considerably augmented in multiple types of cancers, like BLCA, breast cancer, cholangiocarcinoma, colon adenocarcinoma, and kidney renal clear cell carcinoma (Fig. 1A). Through RNA-seq analysis of differential expression, upregulated genes were filtered by log2FC > 0.7 and FDR < 0.01in UCB, and notably MTHFD2 was considered to be statistically significant (log2FC = 0.789 and FDR = 0.002) (Fig. 1B, Table S1). Furthermore, the results of western blot analysis manifested higher expression of MTHFD2 in human BLCA cells (BIU-87, 5637, EJ, T24, and TCCSUP) than SV-HUC-1 cells (Fig. 1C). We also performed quantification gel analysis on the WB results. We obtained that the densities of BLCA cell bands was significantly higher than that of the SV-HUC-1 (control) cells band (Fig. 1C). By comparing 414 UCB samples and 19 normal bladder tissue samples from RNA-seq data, the unpaired tissue contrast displayed that MTHFD2 expression was elevated in UCB samples (p = 3.8e-4) (Fig. 1D). The same results were seen in the comparison between 19 UCB samples and their paired normal bladder tissue samples (p value = 1.6e-4) (Fig. 1E). In order to make a robust conclusion, we performed immunohistochemistry (IHC) for the tumor and normal tissues of three BLCA patients. MTHFD2 was used for staining. It is clearly seen that the tumor tissues have higher MTHFD2 expressions than normal tissues (Fig. 1F), confirming that the MTHFD2 gene expression is elevated in BLCA (Table.S1_F).

Survival analysis and cox regression analysis
Kaplan-Meier survival analysis documented that the high expression of MTHFD2 evidently diminished the overall survival (OS, p = 0.002, Fig. 3A), disease-specific survival (p = 0.005, Fig. 3B), and progress-free interval (p = 0.005, Fig. 3C) of patients with UCB. Table 2 and Fig. 3D depicted the results of univariate and multivariate Cox regression analyses for theDSS of patients with UCB. From the univariate Cox regression model, subtype [papillary versus non-papillary, the hazard ratio    (Fig. 3D).

Illustration of the high expression level of of MTHFD2 by GSEA
Totally 508 gene sets were found to be substantially enriched in MTHFD2 high expression phenotype from different pathway databases (Table S2). Partial gene sets of interest were visualized. We focused on those gene sets which were associated with cancer growth, progression, and metastasis, such as nuclear factor κB (NF-κB) activation, mitotic phases, Janus kinase/signal transducer and activator of transcription (JAK/STAT), cancer immunotherapy by programmed death 1 (PD1) blockade, signaling pathway by epidermal growth factor receptor (EGFR) in cancer, mitogen-activated protein kinase (MAPK) family signaling cascades, phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), senescence, and autophagy in cancer pathways (Fig. 4). For further validation of our assumption, we downloaded two sets of RNA-Seq expression data from CCLE (Cancer Cell Line Encyclopedia). These two data sets came from the UMUC10 and BFTC905 cell lines (two BLCA cell lines), respectively. The essential pathways like the MAP, STAT, NF-KB, cell cycle and autophagy pathways were examined (Fig. 5A and B). They also exhibited significantly high expression levels and thus were activated in BLCA cells.

CCK8 and FACS experiments verified the oncogenic role of MTHFD2
To further experimentally verify the oncogenic role of MTHFD2 gene, we knocked down MTHFD2 with two siRNAs in two BLCA cell lines, respectively ( Fig. 7A and   B). The OD value detection revealed that the control cells progressed significantly faster than the two si-MTHFD2 cell lines (Fig. 7C and D), suggesting that MTHFD2 might contribute to BLCA cell growth/proliferation. Next, we performed FACS (Fluorescence-activated Cell Sorting) of control and si-MTHFD2 cells. We consider that a higher fraction of cells in G1 (gap1) phase represents a less actively dividing state of cells which means less likelihood to promote oncogenesis, while a higher fraction in S (synthesis) phase indicates more dividing cells. Not surprisingly, we observed that control cells had discernibly lower fractions of cells (~ 5% difference) in G1 phase ( Fig. 7E and F). This suggests that MTHFD2 might have promoted the transition from G1 to S phase to regulate cell cycle and consequently contribute to the oncogenesis of bladder cancer.

Discussion
Given the fact that the currently known biomarkers of UCB are still unable to be applied to clinical practice or provide any guidance for the subsequent treatment, it is necessary to discover a novel and reliable biomarker. Early diagnosis of UCB is the key to improve the prognosis of patients. Plenty of researches have reported some prognostic biomarkers for BLCA, including protein biomarkers, genomic biomarkers, epigenetic biomarkers, and transcriptomic biomarkers, such as fibroblast growth factor receptor 3 (FGFR3), Telomerase reverse transcriptase (TERT) mutation, One cut domain family member 2 (ONECUT2), polymerase (RNA) III (DNA directed) polypeptide G (POLR3G), Cyclin A1 (CCNA1), B cell lymphoma 2 (BCL2), Eomesodermin (EOMES), Vimentin (VIM), and high-temperature requirement A serine peptidase 1 (HtrA1) [27,28] . Our study results indicated  that MTHFD2 was a potential prognostic biomarker of UCB patients, which can be a new choice to be applied in the clinic. MTHFD2 is a bifunctional enzyme existing in mitochondrion with nicotinamide adenine dinucleotide-specific dehydrogenase activity [29]. MTHFD2 takes crucial part in mitochondrial folate-mediated one-carbon pathway, and meanwhile, it is consistently overexpressed in embryos and a wide range of tumors [30].
Previous study reported that Carolacton (a natural product of MTHFD2 inhibitor tool compound) was able to restain the growth of different human tumor cell lines [31]. Then, an isozyme-selective MTHFD2 inhibitor, DS18561882, was discovered to repress the proliferation of breast cancer cell lines and the tumor growth in a mouse xenograft model with breast carcinoma upon oral administration [32]. The regulatory factors and mechanisms of elevated MTHFD2 expression in various cancer types need to be clarified, since MTHFD2 is a promising novel target for anti-cancer therapy [33].
The functions of MTHFD2 in UCB have not been previously reported clearly, so we wonder if MTHFD2 also plays a crucial part in BLCA. Our study elaborated that MTHFD2 was highly expressed in various types of tumors, including UCB. The expression of MTHFD2 in UCB tissues was evidently higher than that in normal bladder tissues. We could get the same conclusion in the comparison of both unpaired and paired bladder tissue samples. The result of western blot showed that MTHFD2 expression was higher in UCB cell lines than in the SV-HUC-1 cell line. IHC analysis further confirmed higher expression in BLCA tissue than paired normal bladder tissue. Through these results, we knew that during UCB tumorigenesis, MTHFD2 expression is a cumulative alteration.
Our study uncovered that MTHFD2 upregulation is noticeably associated with high T stage, high M stage, high histologic grade, and high pathologic stage. Those clinical features all predicted the poor clinical outcome. Furthermore, MTHFD2 expression is potently enhanced in non-papillary UCB. It is obvious that compared to papillary subtype, non-papillary UCB is more invasive and that most of them could cause shortened survival due to metastatic spread [34]. Then, we conducted Kaplan Meier survival analysis, univariate analysis, and multivariate analysis on the DSS. The result manifested that lymphovascular invasion, and high MTHFD2 expression were considered to be correlated with the poor prognosis, and that MTHFD2 was regarded as an independent prognostic factor for the DSS in patients with UCB.
GSEA was further implemented to decipher the mechanism of MTHFD2 functioning in UCB, the result of which suggested that numerous signaling pathways were enriched in MTHFD2 high expression group, including NF-κB activation, mitotic phases, JAK/STAT, cancer immunotherapy by PD1 blockade, signaling pathway by EGFR in cancer, MAPK family signaling cascades, PI3K/ AKT/mTOR, and senescence and autophagy in cancer pathways. The essential pathways like the MAP, STAT, NF-KB, and autophagy pathways were also exhibited significantly high expression levels and were activated in BLCA cells such as UMUC10 and BFTC905. Some of them were already reported in other carcinomas by prior works [17][18][19][20]30]. Our follow-up studies interrogated Significance was calculated by. One-way ANOVA *, P < 0.05; **, P < 0.01. C, D The OD value at different time points. Significance was calculated by Two-way repeated measures ANOVA. *, P < 0.05; **, P < 0.01; ***, P < 0.001. E, F FACS (Fluorescence-activated Cell Sorting) of control and si-MTHFD2 cells. Higher fraction in G1 phase represents a less actively dividing state of cells which means less likely to promote oncogenesis the molecular mechanisms of MTHFD2 in UCB to find a potential anti-cancer target.
Immunotherapy is a vital part of clinical treatment for UCB. Intravesical BCG has been regarded as the most effective immunotherapy for NMIBC due to its approval by U.S. Food and Drug Administration (FDA) in 1990, which is proved to reduce recurrence and prolong survival [35,36]. As for metastatic UCB, immune checkpoint inhibitors have recently manifested to have good activity and significant efficacy. The first target was CTLA4 that could interact with CD80/86 to restrict T-cell activation [37]. Ipilimumab and tremelimumab, the monoclonal antibodies targeting CTLA4, were developed. Some scientists found that drugs directly against either PD1 or PD-L1 had lower adverse effects than CTLA4 inhibitors for their direct action in tumor microenvironment [38]. The interaction of the PD1 signaling pathway, such as the PD1 receptor and its 2 ligands, activated a cascade of events and decreased cytokine secretion, T-cell activation, and targeted cell lysis [26]. PD1/PD-L1 antibodies, therefore, improved antitumor immunity. PD-L1 inhibitors, Atezolizumab and Durvalumab, were both approved by FDA for the treatment of patients with inoperable or metastatic UCB progressing on platinum-based treatment with positive PD-L1 [39]. A PD1 inhibitor, Pembrolizumab, has been approved in the first-line treatment of UCB patients ineligible for cisplatin with tumor PD-L1 positive [40]. These immune checkpoint inhibitors were exhibited to have significant efficacy and bring obvious survival benefits to patients with metastatic UCB [39].
Above all, the level of immune infiltration is apparently associated with the UCB prognosis. Meanwhile, immune infiltration can be a prognostic indicator of immunotherapy response. Therefore, it is a crucial part of treatment for UCB to identify valid predictive biomarkers for immune checkpoint inhibitor therapy. We noticed that cancer immunotherapy by PD1 blockade pathway was considerably enriched in MTHFD2 high expression group by GSEA. Then we wonder if MTHFD2 expression is correlated with immune infiltrates.
From the lollipop diagrams, we knew that MTHFD2 expression was positively correlated with Th2 cells, Th1 cells, macrophages, aDC, and Tgd immune cells. It was reported that the efficient response to BCG in UCB required Th1-type immunity, and that Th2-promoting factors could trigger Th1-type immunity contributing to the treatment of BCG [41]. Secondly, tumor-associated macrophages had two functional states including M1 (anti-tumor) and M2 (tumor-promoting). The increased ratio of M1/M0 might correlate to the improved prognosis of UCB [42]. In prior researches, the high level of CD8+ T cells was indicated to trigger the improved prognosis and the augmented possibility of response to immunotherapy, which was the basic mechanism of immune checkpoint inhibitors [43][44][45]. Of note, CD4+ T cells and dendritic cells were also illustrated to be supportive in this process [46]. Taken together, MTHFD2 expression was significantly associated with the level of those infiltrating immune cells which were indicators of disease prognosis and assumed a central role in immunotherapy for UCB. Moreover, we found that several immune checkpoint molecules exhibited close association with MTHFD2 expression, including PDCD1, CD274, CTLA4, CD276, CSF1R, IDO1, LAG3, HAVCR2, and TIGIT. In summary, MTHFD2 might be a new target of anti-tumor immunity, which contributes to the orchestration of immune cell infiltrates and the expression of immune checkpoint molecules. This potential mechanism could demonstrate the reason why improved prognosis was observed in patients with poor MTHFD2 expression. The MTHFD2 inhibitors may provide an effective way for the treatment of UCB.
As the results of CCK8 and FACS experiments shows, MTHFD2 might contribute to BLCA cell growth/proliferation via regulating cell cycle. Our following study will continue to figure out if MTHFD2 could drive tumor cell proliferation, migration, and cycle progression and inhibit cell apoptosis in UCB, just as in other tumors, and to study the potential direct or indirect mechanism. Furthermore, we will research the anti-tumor work of the MTHFD2 inhibitors to find a selective target for immunotherapy.

To our best knowledge, this is the first study demonstrating the prognostic role and immune infiltration level of MTHFD2 in UCB
We concluded that MTHFD2 was an independent prognostic factor for the DSS of patients with UCB and could be a potential biomarker of disease prognosis. MTHFD2 also might be a new target of anti-tumor immunity for its strong association with immune infiltration. There are some limitations in this study. Firstly, the clinical data downloaded from TCGA was limited and incomplete. Our study findings need to be validated in larger and multi-center cohort studies. Secondly, the prognostic ability of MTHFD2 in UCB was lack of validation from adequate clinical samples. Otherwise, the anti-tumor mechanisms of MTHFD2 and the potential targets for immunotherapy in UCB need to be elucidated via molecular experiments.